The Safety, Immunogenicity, and Acceptability of Inactivated Influenza Vaccine Delivered by Microneedle Patch (TIV-MNP 2015): A Randomised, Partly Blinded, Placebo-controlled, Phase 1 Trial
Document Type
Article
Publication Date
6-27-2017
Publication Title
The Lancet
Volume
390
Issue
10095
First page number:
649
Last page number:
658
Abstract
Background
Disciplines
Public Health
Language
English
Repository Citation
Rouphael, N. G.,
Paine, M.,
Mosley, R.,
Henry, S.,
McAllister, D. V.,
Kalluri, H.,
Pewin, W.,
Frew, P. M.,
Yu, T.,
Thornburg, N. J.,
Kabbani, S.,
Lai, L.,
Vassilieva, E. V.,
Skountzou, I.,
Compans, R. W.,
Mulligan, M. J.,
Prausnitz, M. R.
(2017).
The Safety, Immunogenicity, and Acceptability of Inactivated Influenza Vaccine Delivered by Microneedle Patch (TIV-MNP 2015): A Randomised, Partly Blinded, Placebo-controlled, Phase 1 Trial.
The Lancet, 390(10095),
649-658.
http://dx.doi.org/10.1016/S0140-6736(17)30575-5